Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 13/20 | 0.50 |
| ▸ | DDB1 | Q16531 | 12/20 | 0.50 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | TNF | P01375 | 1/20 | 0.39 |
| ▸ | IL1B | P01584 | 1/20 | 0.39 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.39 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4929916 | 0.89 | CRBN (0.48) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| Diethyl Hydrogen Phosphate SCHEMBL5476334 | 0.86 | L3MBTL1 (0.39) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| Gamma-Aminobutyric Acid SCHEMBL5482454 | 0.86 | DDB1 (0.39) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL4103132 | 0.85 | DDB1 (0.50) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL4939061 | 0.85 | ALDH1A1 (0.46) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL24421112 | 0.84 | CRBN (0.55) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL4120260 | 0.83 | ALDH1A1 (0.50) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL4119644 | 0.82 | CASP3 (0.49) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| Glycine SCHEMBL4929867 | 0.81 | DDB1 (0.41) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| Bromoacetic Acid SCHEMBL4940372 | 0.81 | DDB1 (0.41) | CRBNDDB1IKZF3ALDH1A1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070293517-A1 | Derivatives Of Chemotherapeutic Agents With A Formaldehyde Releasing Moiety | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2007-12-20 | — | — | US | claimed |
| WO-2005120577-A2 | DERIVATIVES OF CHEMOTHERAPEUTIC AGENTS WITH A FORMALDEHYDE RELEASING MOEITY | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2005-12-22 | — | — | WO | claimed |
| EP-4002342-B1 | DISPLAY PANEL AND DISPLAY DEVICE | BOE TECHNOLOGY GROUP CO LTD (CN) | 2026-03-04 | — | — | EP | disclosed |
| US-12273025-B2 | Power supply apparatus | POON NGAI KIT FRANKI (CN) | 2025-04-08 | — | — | US | disclosed |
| US-11994512-B2 | Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2024-05-28 | — | — | US | disclosed |
| US-20240141035-A1 | Anti-Il-22 Antibodies, Antibody Fragments,Their Immunoconjugates And Uses Thereof | BIOATLA, INC. (US) | 2024-05-02 | — | — | US | disclosed |
| CN-114008702-B | Display panel and display device | 京东方科技集团股份有限公司 | 2024-02-27 | — | — | CN | disclosed |
| EP-3818638-B1 | BEAM MANAGEMENT METHODS AND APPARATUS | MIXCOMM INC (US) | 2024-02-14 | — | — | EP | disclosed |
| US-11834472-B2 | Anti-IL-22 antibodies, antibody fragments, their immunoconjugates and uses thereof | BIOATLA, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-11825326-B2 | Beam management methods and apparatus | Mixcomm, Inc. (US) | 2023-11-21 | — | — | US | disclosed |
| CN-116990474-A | Water quality detection system and detection method for power plant | 国电电力邯郸东郊热电有限责任公司 | 2023-11-03 | — | — | CN | disclosed |
| US-20070293517-A1 | Derivatives Of Chemotherapeutic Agents With A Formaldehyde Releasing Moiety | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2007-12-20 | — | — | US | disclosed |
| US-20060094730-A1 | having increased bioavailability when administered orally or by injection; used for treating erythema, behcet's syndrome, crohn's disease, rheumatoid arthritis, abnormal myeloidosis syndrome and tumors | ZHANG, HESHENG (CN) | 2006-05-04 | — | — | US | disclosed |
| WO-2005120577-A2 | DERIVATIVES OF CHEMOTHERAPEUTIC AGENTS WITH A FORMALDEHYDE RELEASING MOEITY | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2005-12-22 | — | — | WO | disclosed |
| WO-2005120577-A2 | DERIVATIVES OF CHEMOTHERAPEUTIC AGENTS WITH A FORMALDEHYDE RELEASING MOEITY | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2005-12-22 | — | — | WO | disclosed |
| EP-1607394-A1 | WATER-SOLUBLE THALIDOMINE DERIVATIVES | Tian Jin Hemay Bio-Tech Co., Ltd. (DE) | 2005-12-21 | — | — | EP | disclosed |
| US-20040077685-A1 | Analogs of thalidomide as potential angiogenesis inhibitors | HEALTH AND HUMAN SERVICES, THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF | 2004-04-22 | — | — | US | disclosed |
| EP-1389203-A2 | ANALOGS OF THALIDOMIDE AS POTENTIAL ANGIOGENESIS INHIBITORS | The Governement of the United States of America, represented by The Secretary Department of Health and Human services (US) | 2004-02-18 | — | — | EP | disclosed |
| WO-2002068414-A3 | ANALOGS OF THALIDOMIDE AS POTENTIAL ANGIOGENESIS INHIBITORS | GOVERNEMENT OF THE UNITED STAT (US) | 2002-10-17 | — | — | WO | disclosed |
| WO-2002068414-A2 | ANALOGS OF THALIDOMIDE AS POTENTIAL ANGIOGENESIS INHIBITORS | THE GOVERNEMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2002-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077685-A1 | Analogs of thalidomide as potential angiogenesis inhibitors | FLT4, TEK, VEGFA | CRBN 315/4885DDB1 782/4885IKZF3 2027/4885 |
| US-20070293517-A1 | Derivatives Of Chemotherapeutic Agents With A Formaldehyde Releasing Moiety | DHFR, FAU, MYD88 | CRBN 931/4885DDB1 740/4885IKZF3 957/4885 |
| US-20060094730-A1 | having increased bioavailability when administered orally or by injection; used for treating erythema, behcet's syndrome, crohn's disease, rheumatoid arthritis, abnormal myeloidosis syndrome and tumors | FCGRT, MALT1, IL1R1 | CRBN 300/4885DDB1 1471/4885IKZF3 1649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.